Digital chronic kidney disease tools are falling short on their goals of improving patient outcomes and reducing costs, adding to the mixed results of digital health technology.

Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce ...

Bayer just scored another label expansion for its blockbuster-in-waiting, Kerendia. | The heart and kidney med earned the first FDA nod in three decades for adults with chronic kidney disease ...

Heart disease and chronic kidney disease can accelerate one another, but new guidelines say simple screening and early ...

A new international study has offered fresh hope to millions of people living with chronic kidney disease (CKD) who do not have diabetes. Researchers have found that Finerenone, a once-daily ...

Most people rarely think about their kidneys until they stop working as they should. Yet these organs play a vital role every day, filtering waste from the blood and helping keep the body in balance.

Marie Evans studies how the risk of kidney disease can be detected earlier and how well different treatments work. Meet one of the new professors of ...

Consumer-focused guidance emphasizes CKD testing, individualized care, evidence review, and caution around "reversal" ...

The Trump administration is rapidly expanding its 10-year ACCESS Model, a value-based payment program that reimburses digital ...

A new research project launched by Kidney Wales and Aston University will explore how living with chronic kidney disease ...

Rates of the disease have been rising for decades, driven in part by diabetes and high blood pressure. By Nina Agrawal The number of adults with chronic kidney disease is growing, according to a study ...